Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Arbutus Biopharma's annualizedNet Income for the quarter that ended in Mar. 2026 was $678.8 Mil. Arbutus Biopharma's average total tangible assets for the quarter that ended in Mar. 2026 was $185.9 Mil. Therefore, Arbutus Biopharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 365.15%.
The historical rank and industry rank for Arbutus Biopharma's Return-on-Tangible-Asset or its related term are showing as below:
ABUS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -220 Med: -47.65 Max: 116.5
Current: 116.5
During the past 13 years, Arbutus Biopharma's highest Return-on-Tangible-Asset was 116.50%. The lowest was -220.00%. And the median was -47.65%.
ABUS's Return-on-Tangible-Asset is ranked better than 99.36% of 1412
companies
in the Biotechnology industry
Industry Median: -35.475
vs ABUS: 116.50
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Arbutus Biopharma Return-on-Tangible-Asset Related Terms
Arbutus Biopharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABUS vs EVMN, ANNX, TBPH: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Arbutus Biopharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 365.15% mean?
Arbutus Biopharma (ABUS) has a Return-on-Tangible-Asset of 365.15% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Arbutus Biopharma and its competitors. According to the industry distribution chart, Arbutus Biopharma ranks #9 out of 1412 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Arbutus Biopharma's Return-on-Tangible-Asset too high?
Arbutus Biopharma's current Return-on-Tangible-Asset is 365.15%. Based on the distribution chart, Arbutus Biopharma ranks #9 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Return-on-Tangible-Asset compare to EVMN and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #9 out of 1412 companies for Return-on-Tangible-Asset. This places Arbutus Biopharma in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current Return-on-Tangible-Asset is 365.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.03, compared to a current price of $5.21 — trading 89.8% below its estimated fair value. The current Return-on-Tangible-Asset is 365.15%. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Return-on-Tangible-Asset is 365.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $5.21 is trading 89.8% below its estimated GF Value™ of $51.03.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Return-on-Tangible-Asset: 365.15%
GF Value™: $51.03 vs. price of $5.21 (89.8% below fair value)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score
Get the complete analysis for ABUS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
